Itoprid Fmk (Itopride Hydrochloride)

Itoprid Fmk (itopride hydrochloride) is indicated for several functional gastrointestinal conditions characterized by delayed gastric emptying and dysmotility.

• Functional dyspepsia: reduces post‑prandial fullness, early satiety and epigastric pain by enhancing gastric emptying.
• Gastric motility disorders: improves coordinated stomach contractions, facilitating more efficient transit of contents through the upper gastrointestinal tract.
• Gastroesophageal reflux disease (GERD): augments lower esophageal sphincter tone and accelerates clearance of refluxed acid, helping to control heartburn symptoms.

• Itopride hydrochloride exerts its gastroprokinetic effect by antagonizing peripheral dopamine D2 receptors, which removes dopaminergic inhibition of gastrointestinal motility. Concurrently, it inhibits acetylcholinesterase, leading to increased acetylcholine levels at muscarinic receptors in the gut wall. The combined actions enhance coordinated smooth‑muscle contractions, promote gastric emptying, and improve lower esophageal sphincter function. These mechanisms collectively restore normal motility patterns in the upper digestive tract.

Adverse reactions to Itoprid Fmk are generally mild, but clinicians should be aware of both common and rare events.

Common Side Effects

• Dry mouth: reduced salivary secretion causing throat discomfort.
• Diarrhea: increased bowel movements with loose stools.
• Nausea: sensation of unease or urge to vomit.
• Headache: mild to moderate cranial pain.

Serious or Rare Side Effects

• Extrapyramidal symptoms: involuntary muscle movements or rigidity.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

Before prescribing Itoprid Fmk, consider the following precautions to ensure safe use.

• Renal impairment: adjust use or monitor renal function in patients with reduced kidney clearance.
• Hepatic disease: use cautiously in individuals with liver dysfunction, monitoring liver enzymes.
• Concomitant dopamine antagonists: may diminish therapeutic effect; assess need for dose adjustment.
• Elderly patients: start at lower dose and monitor for increased sensitivity to side effects.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Itoprid Fmk may interact with other medicines; awareness of major and moderate interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Anticholinergic agents: may counteract prokinetic action, reducing therapeutic benefit.
• Strong CYP3A4 inhibitors: could increase plasma levels of itopride, raising risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Metoclopramide: additive dopaminergic blockade may enhance gastrointestinal effects.
• Antidepressants (SSRIs, SNRIs): potential for increased serotonergic activity, monitor for nausea.
• Diuretics: enhanced gastrointestinal motility may affect electrolyte balance; observe patient status.